Abstract:Purpose: Meiotic nuclear division 1 (MND1) is a meiosis-specific protein that promotes lung adenocarcinoma progression. However, its expression and biological function across cancers remain largely unexplored. Patients and methods: The expression, prognostic significance, mutation status, and methylation profile of MND1 in various cancers were comprehensively analyzed using the TIMER, GTEX, Kaplan-Meier plotter, cBioPortal, and GSCA databases. Additionally, we constructed a PPI network, enrichment analysis and single-cell transcriptomic sequencing to elucidate the underlying mechanism of MND1. Furthermore, we investigated the association between MND1 expression and drug sensitivity using CellMiner. Moreover, we also explored the correlation between MND1 expression and immune infiltration. Finally, we validated the functional role of MND1 in breast cancer through IHC staining, CCK8, EdU, colony formation, and flow cytometry assays. Results: MND1 has been reported to be highly expressed in Pan-cancer, High MND1 expression was significantly associated with poor prognosis in cancers. Additionally, MND1 mutation frequency is high in most cancers, and its expression correlates with methylation. Furthermore, MND1 expression significantly correlates with immune checkpoint blockade (ICB) markers, including PD-L1, PD-1, and CTLA-4. The PPI network reveals interactions between MND1 and PSMC3IP, BRCA1, and BRCA2. Enrichment analysis and single-cell sequencing indicate that MND1 positively correlates with cell cycle. ROC curve reveals favorable diagnostic efficacy of MND1 in breast cancer. In vitro, MND1 overexpression promotes breast cancer cell proliferation and increases the expression of key cell cycle regulators (CDK4, CDK6, and cyclin D3), accelerating the G1/S phase transition and leading to abnormal breast cancer cell proliferation. The immunohistochemical analysis revealed a robust expression of MND1 in breast cancer tissues, exhibiting a significant positive correlation with PD-L1 and FOXP3. Conclusion: MND1 is an oncogene and may serve as a biomarker for cancer prognosis and immunotherapy. Targeting MND1 may be a potential tumor treatment strategy.

Functional Cooperation Between Co-Amplified Genes Promotes Aggressive Phenotypes of HER2-positive Breast Cancer.

HER2-Driven Breast Tumorigenesis Relies Upon Interactions of the Estrogen Receptor with Coactivator MED1.

Modeling Time-Dependent Transcription Effects Of Her2 Oncogene And Discovery Of A Role For E2f2 In Breast Cancer Cell-Matrix Adhesion

HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

MUC1 Triggers Lineage Plasticity of Her2 Positive Mammary Tumors

Amplification of Hsa-Mir-191/425 Locus Promotes Breast Cancer Proliferation and Metastasis by Targeting DICER1

Essential role of MED1 in the transcriptional regulation of ER-dependent oncogenic miRNAs in breast cancer

MED1 induces M2 polarization of tumor-associated macrophages to aggravate breast cancer

Pparγ1 Facilitates ErbB2-Mammary Adenocarcinoma in Mice

Cooperative Oncogenic Effect and Cell Signaling Crosstalk of Co-Occurring HER2 and Mutant PIK3CA in Mammary Epithelial Cells

MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway

Key Roles for Med1 Lxxll Motifs in Pubertal Mammary Gland Development and Luminal-Cell Differentiation

HER2-intronic miR-4728-5p facilitates HER2 expression and accelerates cell proliferation and migration by targeting EBP1 in breast cancer

Global Expression Profiling and Pathway Analysis of Mouse Mammary Tumor Reveals Strain and Stage Specific Dysregulated Pathways in Breast Cancer Progression.

Integrative Pan-Cancer Analysis Reveals the Oncogenic Role of MND1 and Validation of MND1's Role in Breast Cancer

miR-205 Regulates Tamoxifen Resistance by Targeting Estrogen Receptor Coactivator MED1 in Human Breast Cancer

HER2 Phosphorylation Induced by TGF-β Promotes Mammary Morphogenesis and Breast Cancer Progression.

Amplitude modulation of androgen signaling by c-MYC.

ME1 promotes basal-like breast cancer progression and associates with poor prognosis

A C->T Variation in 3'-Untranslated Region Elevates MED12 Protein Level in Breast Cancer That Relates to Better Prognosis

MED27 Plays a Tumor‐promoting Role in Breast Cancer Progression by Targeting KLF4